China Biologic Products to Report Fourth Quarter and Fiscal Year 2013 Financial Results

BEIJING, March 4, 2014 /PRNewswire/ -- China Biologic Products, Inc. CBPO "China Biologic" or the "Company"), a leading fully integrated plasma-based biopharmaceutical company in China, today announced that the Company plans to release fourth quarter and fiscal year 2013 financial results on Wednesday, March 12, 2014 after the market closes.

The Company's management will hold a conference call at 8:00 a.m. ET on Thursday, March 13, 2014, which is 8:00 p.m., Beijing Time on March 13, 2014, to discuss fourth quarter and fiscal year 2013 results. Listeners may access the call by dialing:

A telephone replay will be available one hour after the conclusion of the conference call through 9:00 a.m., Eastern Time on March 20, 2014. The dial-in details are:

A live and archived webcast of the conference call will be available through the Company's investor relations website at http://chinabiologic.investorroom.com/.

About China Biologic Products, Inc.

China Biologic Products, Inc. CBPO, is a leading fully integrated plasma-based biopharmaceutical company in China. The Company's products are used as critical therapies during medical emergencies and for the prevention and treatment of life-threatening diseases and immune-deficiency related diseases. China Biologic is headquartered in Beijing and manufactures over 20 plasma-based products through its indirect majority-owned subsidiaries, Shandong Taibang Biological Products Co., Ltd. and Guiyang Dalin Biologic Technologies Co., Ltd. The Company also has an equity investment in Xi'an Huitian Blood Products Co., Ltd. The Company sells its products to hospitals and other healthcare facilities in China. For additional information, please see the Company's website www.chinabiologic.com.

Contact:

China Biologic Products, Inc.
Mr. Ming Yin
Vice President
Phone: +86-10-6598-3099
Email: ir@chinabiologic.com

ICR Inc.
Mr. Bill Zima
Phone: +86-10-6583-7511 or +1-646-405-5191
E-mail: william.zima@icrinc.com

SOURCE China Biologic Products, Inc.